Concord Medical Services Holdings Ltd (CCM)
0.5001
-0.10
(-17.12%)
USD |
NYSE |
May 31, 16:00
Concord Medical Services Holdings SG&A Expense (Annual): 54.62M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 54.62M |
| December 31, 2022 | 55.48M |
| December 31, 2021 | 62.17M |
| December 31, 2020 | 46.45M |
| December 31, 2019 | 50.00M |
| December 31, 2018 | 47.43M |
| December 31, 2017 | 41.69M |
| December 31, 2016 | 41.46M |
| Date | Value |
|---|---|
| December 31, 2015 | 39.11M |
| December 31, 2014 | 24.12M |
| December 31, 2013 | 30.76M |
| December 31, 2012 | 18.20M |
| December 31, 2011 | 18.25M |
| December 31, 2010 | 12.37M |
| December 31, 2009 | 5.497M |
| December 31, 2008 | 3.512M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
46.45M
Minimum
2020
62.17M
Maximum
2021
53.75M
Average
54.62M
Median
2023
SG&A Expense (Annual) Benchmarks
| Dr Reddy's Laboratories Ltd | 1.434B |
| ASLAN Pharmaceuticals Ltd | 13.24M |
| Zai Lab Ltd | 281.61M |
| 111 Inc | 95.08M |
| Sinovac Biotech Ltd | 466.32M |